Study identity card

BLOC

Austria Finland Germany Spain Switzerland
Share
  • Disease: Post-COVID-19
  • Study type: Randomised Clinical Trial
  • Study type descriptors: Interventional
  • Study aim: To investigate the efficacy, pharmacodynamics and safety of BC 007 in improving long COVID symptoms by neutralising functional autoantibodies targeting G-protein
  • Number of participants enrolled: 119
  • Study enrolling from to
  • Study includes follow-up for 3 months

Study Data

  • Adults
  • Elderly
  • General population
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • BC 007

Other information

Funders:

  • Berlin Cures GmbH

If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it

The data is updated up to